Playbook Investors Network is proud to have Shaun Hawkins as Managing Partner. He consults extensively on management, operational, strategic challenges, and financial issues. He uses a hands-on approach to support clients and focuses most of his time on proactive planning, analysis and client communication. He is a dedicated professional who is focused on increasing enterprise value.
Hawkins is also the founder of the ProSyte Companies, a diversified holding entity investing in businesses and real estate in the US and Europe. Investments include: Auxigen Health, BioPharm Nutraceuticals and Carrick Therapeutics.
From 2012 until his departure in 2015, Hawkins was vice president of new ventures and private equity investing at Eli Lilly and Company. He was responsible for the company’s venture capital, private equity and venture formation activities, managing over $1.4 billion.
In 2009, Hawkins was promoted to chief diversity officer to lead the development and implementation of Lilly’s global diversity and inclusion strategy. Lilly received national recognition for its efforts and progress during Hawkins’ tenure.
Prior to his promotion, Hawkins was director of private equity where he built strategic investment syndicates and new entities to accelerate the development of early-stage innovation. He joined Lilly in 2001 and held various roles in sales and corporate business development. In 2007, he was certified as a Six Sigma black belt.
Hawkins currently serves on the board of directors for Invesque Inc. (TSX: IVQ.U), where he chairs the audit and investment committees. He previously chaired the investment committee and served as a member of the audit as well as the compensation, nominating and governance (CNG)committees for Mainstreet Health Investments (TSX: HLP.U). He was the previous board chair for Audion Therapeutics (Netherlands) and Muroplex Therapeutics (US) as well as a board member of the Accelerator Corporation (US), Immuneworks Inc. (US) and Zymeworks Inc. (Canada). Hawkinswas also a member of the limited partner advisory committees of BioCrossroads’ Indiana Enterprise Fund (US), Epidarex Capital (UK), the Indiana Future Fund/INext Fund (US) and TVM Capital (Canada and Germany). In 2017, Hawkins earned a Board Governance Fellowship from the National Association of Corporate Directors (US).
Hawkins graduated magna cum laude with a bachelor’s degree in business from the University of Tennessee in 1995. In 2000, he received a master’s degree in business administration from the Kellogg School of Management at Northwestern University.